Showing results (41-50 of 61) with videos related to

Sort By:
Pageof 7
Plos One|April 4, 2012
S100A9 interaction with TLR4 promotes tumor growthEva Källberg, Thomas Vogl, David Liberg, et al.
European Journal of Cancer (Oxford, England : 1990)|April 15, 2014
High density of S100A9 positive inflammatory cells in prostate cancer stroma is associated with poor outcomeViktor Tidehag, Peter Hammarsten, Lars Egevad, et al.
Plos One|May 14, 2013
Common interactions between S100A4 and S100A9 defined by a novel chemical probePer Björk, Eva Källberg, Ulf Wellmar, et al.
Arthritis Research & Therapy|April 16, 2011
Protein synthesis of the pro-inflammatory S100A8/A9 complex in plasmacytoid dendritic cells and cell surface S100A8/A9 on leukocyte subpopulations in systemic lupus erythematosusChristian Lood, Martin Stenström, Helena Tydén, et al.
Rheumatology (Oxford, England)|August 15, 2013
Increased serum levels of S100A8/A9 and S100A12 are associated with cardiovascular disease in patients with inactive systemic lupus erythematosusHelena Tydén, Christian Lood, Birgitta Gullstrand, et al.
The Prostate|September 7, 2006
Identification of ABR-215050 as lead second generation quinoline-3-carboxamide anti-angiogenic agent for the treatment of prostate cancerJohn T Isaacs, Roberto Pili, David Z Qian, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 21, 2008
IFN-alpha/beta signaling is required for polarization of cytokine responses toward a protective type 1 pattern during experimental cryptococcosisCarmelo Biondo, Angelina Midiri, Maria Gambuzza, et al.
The Journal of Infectious Diseases|September 20, 2005
Toward the development of an antidisease, transmission-blocking intranasal vaccine for group a streptococcusMichael R Batzloff, Huaru Yan, Mark R Davies, et al.
Arthritis and Rheumatism|December 2, 2011
Pharmacokinetics, tolerability, and preliminary efficacy of paquinimod (ABR-215757), a new quinoline-3-carboxamide derivative: studies in lupus-prone mice and a multicenter, randomized, double-blind, placebo-controlled, repeat-dose, dose-ranging study in patients with systemic lupus erythematosusAnders A Bengtsson, Gunnar Sturfelt, Christian Lood, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 22, 2007
Type I IFN signaling is crucial for host resistance against different species of pathogenic bacteriaGiuseppe Mancuso, Angelina Midiri, Carmelo Biondo, et al.
Pageof 7